Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1247868 | 0.84 | PTPRC (0.32) | KDM4EALDH1A1HPGDACHECA2 | |
| SCHEMBL10382143 | 0.76 | TGM2 (0.32) | CA12CA2CA9 | |
| SCHEMBL3914969 | 0.76 | KDM4E (0.42) | KDM4EALDH1A1HPGDCA12CA1 | |
| SCHEMBL1007936 | 0.74 | LCK (0.37) | KDM4EALDH1A1 | |
| Phenol SCHEMBL4639675 | 0.73 | CA12 (0.41) | CA12CA1CA2CA9 | |
| SCHEMBL4671199 | 0.71 | CA1 (0.49) | KDM4EALDH1A1HPGDCA12CA1 | |
| SCHEMBL34259 | 0.70 | GAA (0.48) | — | |
| SCHEMBL10976920 | 0.69 | XDH (0.44) | KDM4EALDH1A1HPGD | |
| SCHEMBL2591105 | 0.69 | CA2 (0.42) | KDM4EALDH1A1HPGDCA12CA1 | |
| SCHEMBL8654087 | 0.68 | GAA (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487801-B1 | 7-ARYLSULFONAMIDO-2,3,4,5-TETRAHYDRO-1H-BENZO¬D|AZEPINE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2006-04-19 | — | — | EP | disclosed |
| US-20050090485-A1 | 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | US | disclosed |
| EP-1487801-A1 | 7-ARYLSULFONAMIDO-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003068751-A1 | 7-ARYLSULFONAMIDO-2,3,4,5-TETRAHYDRO-1H-BENZO'DIAZEPINE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY FOR THE REATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| EP-0331130-B1 | CARBAMIC ACID ESTER OF SUBSTITUTED 7-HYDROXY-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES | NOVO NORDISK A/S (DK) | 1993-09-29 | — | — | EP | disclosed |
| US-5017571-A | Prodrugs, mental disorders | NOVO NORDISK A/S (DK) | 1991-05-21 | — | — | US | disclosed |
| EP-0331130-A1 | Carbamic acid ester of substituted 7-hydroxy-2,3,4,5-tetrahydro-1H-3-benzazepines | NOVO NORDISK A/S (DK) | 1989-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090485-A1 | 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders | HTR6, HTR7, HTR2A | DRD2 68/4885DRD4 124/4885KDM4E 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.